Lindy Biosciences, a protein therapeutic formulations firm, has announced a partnership with Novartis Pharmaceuticals to focus more on evolving drugs from Novartis to subcutaneous injections by using their micro classification suspension...
USV Pvt. Ltd. has launched OnArni, a combination of Sacubitril and Valsartan, for treating heart failure, available at an affordable price of Rs. $8 is the cost for each tablet of 50mg. This affordable solution helps tackle the increasing...
Arbele, a leading innovator in biopharmaceutical and biotechnology focused on targeting cadherin-17 (CDH17), has announced a strategic collaboration in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of...
ModeX Therapeutics Inc, a biotechnology company under OPKO Health, Inc., reveals that it has received $35 million more in funding from BARDA, a branch of HHS responsible for Strategic Preparedness and Response in the US. The firm will start...
AstraZeneca, a British company, has partnered exclusively with CSPC Pharmaceutical Group from China to further develop a new small molecule disruptor for Lipoprotein (a) (Lp(a)), which could provide extra benefits for dyslipidemia patients...
Recipharm, a top global pharmaceutical CDMO, is enhancing its pharmaceutical development abilities by making strategic investments and incorporating advanced technologies. This investment enhances its offerings for both early and late-stage...
Liquidia Corporation and Pharmosa Biopharm have updated their exclusive licensing agreement for L606, an inhaled, sustained-release treprostinil formulation. The drug is currently in a clinical trial for treating pulmonary arterial hypertension...
Vaibhav Tewari, Co-Founder and CEO of Portea, engaged in a conversation with India Pharma Outlook, discusses how pharmaceutical companies are leveraging digital innovations such as SaaS platforms, AI-powered chatbots, and secure communication...
.jpg)
Sun Pharma announced that they have signed a worldwide licensing deal to market Philogen's specialty anti-cancer immunotherapy Fibromun (L19TNF) from Switzerland and Italy. bPhilogen is conducting registration trials for Fibromun to treat soft...
Regor Pharmaceuticals (USA), a branch of Regor Therapeutics Group, a biotech company in the clinical testing phase, has agreed to a deal where Genentech, part of the Roche Group, will buy a set of advanced CDK inhibitors from Regor to treat breast...
, CDSCO.jpg)
